close

Agreements

Date: 2011-02-21

Type of information: Collaboration agreement

Compound:

Company: Sanofi Pasteur (France) International Vaccine Institute

Therapeutic area: Infectious diseases

Type agreement:

collaboration

Action mechanism:

Disease: dengue fever

Details:

Sanofi Pasteur, the vaccines division of sanofi-aventis Group is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda. The International Vaccine Institute (IVI) announced the launch of the DVI on February 10, in collaboration with the Sabin Vaccine Institute, the Johns Hopkins University, and the World Health Organization, to support development of vaccines to control dengue fever. The Dengue Vaccine Initiative (DVI) was established in 2010 to build on the work of the Pediatric Dengue Vaccine Initiative and to further awareness of the need to support the development and use of dengue vaccines. The goal of the DVI is to accelerate the introduction of safe and broadly protective vaccines into the national immunization programs of endemic and developing countries. DVI works with scientists, vaccine experts and policy makers from concept to implementation, promoting the development of dengue vaccines while also advocating with governments worldwide to ensure the swift adoption and distribution of a vaccine to those most in need. Sanofi Pasteur’s candidate dengue vaccine—which targets all four virus serotypes— is in Phase 3 clinical study. Phase 3 studies are the ultimate steps in the clinical development of a vaccine before it is submitted to regulatory authorities for evaluation for market authorization. Sanofi Pasteur candidate dengue vaccine has been evaluated in clinical studies (Phase 1, 2) in adults and children in the U.S., Asia and Latin America. Overall, a balanced immune response against all four serotypes was observed after three doses of the vaccine. The vaccine is well tolerated with a similar safety profile after each dose. Clinical studies in adults and children are ongoing in Mexico, Colombia, Honduras, Puerto Rico, Peru, the Philippines, Vietnam, Singapore, Australia, and Thailand.

Financial terms:

Latest news:

Is general: Yes